Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 5Carboplatin 4X-Rays 3Rituximab 3Prednisone 3Nivolumab 3Magnetic Resonance Spectroscopy 3Abiraterone Acetate 3trastuzumab deruxtecan 2talquetamab 2pertuzumab 2pembrolizumab 2olaparib 2niraparib 2erdafitinib 2durvalumab 2belzutifan 2apalutamide 2acalabrutinib 2Trastuzumab 2Sunitinib 2Phantoms, Imaging 2Paclitaxel 2Immunoglobulin G 2Disulfides 2Dexamethasone 2Dasatinib 2Cyclophosphamide 2Crizotinib 2CT-P10 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Drug Therapy × 30 days × Clear all
NCT03409614 2026-05-18

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Regeneron Pharmaceuticals

Phase 3 Completed
789 enrolled 32 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡